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Abstract. Integrin-associated protein (IAP) is a recep- 
tor for the carboxyl-terminal "cell-binding domain" 
(CBD) of thrombospondin 1 (TS1). lAP associates with 
av[33 integrin and mAbs against lAP inhibit certain in- 
tegrin functions. Here we examine the effects of the 
TS1 CBD and 4N1K (KRFYVVMWKK), a cell-bind- 
ing peptide derived from it, on the adhesion and 
spreading on vitronectin (VN) of C32 human mela- 
noma cells which express lAP, 0tv133 , and avl35. Cells ad- 
here to VN at low surface densities via etv[35 and spread 
very slowly while adhesion to higher density VN in- 
volves both etv135 and Otv[33 and results in rapid spread- 
ing. Spreading of the cells, but not adhesion, on sparse 
VN coatings is markedly enhanced by the presence of 
soluble TS1, the recombinant CBD and 4N1K, but not 
the "mutant" peptide 4NGG, KRFYGGMWKK, 
which fails to bind IAP. This enhanced spreading is 
completely blocked by mAb LM609 against 0tv133 and 
the anti-lAP mAb B6H12. Correlated with this en- 
hanced spreading is increased tyrosine phosphorylation 
of focal adhesion kinase (FAK), paxillin, and a protein 
of ca. 90 kD. The enhanced spreading induced by TS1 
and 4N1K and the constitutive spreading on higher 
density VN are both blocked by calphostin C (100 nM), 
wortmannin (10 nM), and tyrosine kinase inhibitors. In 
contrast, pertussis toxin specifically blocks only the TS1 
stimulated spreading on low density VN, indicating that 
lAP exerts its effects on signal transduction via a het- 
erotrimeric Gi protein acting upstream of a common 
cell spreading pathway which includes PI-3 kinase, 
PKC, and tyrosine kinases. 
T 
HE family of thrombospondins has been implicated 
in acute regulation of a number of diverse physio- 
logical processes  such  as platelet  aggregation, in- 
flammation,  angiogenesis,  cell  adhesion  and  migration, 
and other developmental processes (5, 6, 16, 61). The pro- 
totypic member of this family is platelet thrombospondin 
or thrombospondin-1  (TS1). 1 Many cell interaction sites 
and peptides have been identified within the modular TS1 
structure and as many as a dozen different receptors, in- 
cluding several 131 and 133 integrins have been proposed to 
mediate the effects of TS1 on cells (12, 16, 33, 70). Of this 
plethora of putative receptors, the direct binding of TS1 to 
molecularly  characterized  receptors  has  been  demon- 
strated only for HSPGs (40), sulfatides (49), CD36 (1), and 
the integrins Otllb133 and etv133 (33). In the case of the two in- 
tegrins, binding of native TS1 has been demonstrated for 
some cell types, while for other cells, the TS1  RGD se- 
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quence appears to be cryptic (62).  A  number of peptide 
epitopes within the complex TS1 structure have been iden- 
tified with specific functions of the protein. For example, 
sequences within the procollagen-like domain, and two of 
the type 1 (properdin- or malaria-like) repeats inhibit an- 
giogenesis in vivo and  endothelial cell (EC)  motility in 
vitro (65).  Also, a peptide from the amino-terminal hep- 
arin-binding  domain  reverses  focal  adhesions  in  fibro- 
blasts and EC (41, 42) and a tripeptide in one of the type 1 
repeats is capable of activating latent TGF13 thus poten- 
tially influencing cell behavior via this pathway (53). 
In addition to these active sequences in the central pro- 
tease-resistant  stalk-like  region  of the  TS1  subunit,  the 
carboxy terminal domain of TS1 interacts with many cell 
types and has been designated the cell-binding domain or 
CBD. The mAb C6.7 directed to the CBD, has been used 
to implicate this domain of TS1 as a stimulator of motility 
of a number of cell types (37, 38, 64, 71, 72) and to estab- 
lish a role for TS1 in secondary phase or secretion-depen- 
dent platelet aggregation (14). To better define the struc- 
ture-function relationships of the CBD, we expressed it in 
bacteria  exclusive of the nearby RGD  sequence  of TS1 
and established that its cell-binding activity was indepen- 
dent of the RGD site (29). Using overlapping peptides we 
then defined two related active peptide sequences within 
the 221 residues of the CBD: RFYVVM (the minimal C4 
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The peptides competed with one another in cell binding 
assays and both affinity labeled a 52-kD membrane glyco- 
protein CBD receptor candidate (17). We have recently 
identified this 52-kD protein as the widely distributed inte- 
grin-associated protein (lAP or CD47) (7, 18, 35, 36). lAP 
is found in association with av133 and other integrins, and it 
has been implicated in modulating integrin functions re- 
quired for Ca ++ fluxes (54), phagocytosis (4), and cellular 
migration events such as transendothelial (11) and trans- 
epithelial (45) migration of PMNs. The function-blocking 
anti-lAP mAb B6H12 abolishes chemotaxis of human um- 
bilical vein endothelial cells (HUVECs) towards the CBD 
and C4 peptides (18) under conditions in which the HU- 
VECs employ ~v133 integrin for locomotory traction. Fur- 
thermore, both TS1 and RFYVVMWK peptide stimulate 
a Ca ++ transient in IMR90 fibroblasts that is inhibited by 
mAb C6.7 directed against the CBD (in the case of TS1) 
and by anti-IAP mAb B6H12 (66). Taken together these 
data suggest that the CBD can stimulate a chemotactic re- 
sponse  by a  concerted mechanism  in which  Ca ++  regu- 
lated events necessary for cell motility are activated by a 
Ca ++  flux and at the  same time, the function of ~v133 is 
modulated. 
The most studied example of 133 integrin activation is the 
platelet integrin eqtb133 which is maintained in a  state of 
low affinity and avidity on circulating platelets, but is rap- 
idly activated to bind  fibrinogen by thrombin,  epineph- 
rine, and ADP acting via seven transmembrane-spanning 
(7TMS or heptahelical) receptors (56). The signal  trans- 
duction pathway by which these receptors "costimulate" 
fibrinogen binding  by aItb133 is  incompletely understood 
and  complex, involving proximal  heterotrimeric G  pro- 
teins, lipid mediators derived from arachadonic acid via 
both cyclooxygenase and lipoxygenase, which lead to the 
activation of PKC and small G  proteins of the rho family 
(55,  57).  Other  examples of integrin activation such  as 
the  leukocyte CDlla,b,c/CD18  (132) family also  involve 
costimulation  from  7TMS  chemokine  receptors  acting 
through heterotrimeric and  rho family G  proteins, lipid 
mediators, and PKC (60). There is also accumulating evi- 
dence that integrin-mediated cell spreading on a variety of 
matrix proteins requires signal  transduction  events with 
features common to the  pathways  of integrin  activation 
and costimulation, suggesting that some integrins are con- 
stitutively activated  or  can  "autoactivate" to  cause  cell 
spreading.  Chemotaxis and spreading of cells are closely 
allied functions which depend on similar activation states 
of the integrin and similar downstream signal transduction 
events (9, 15, 25, 55). 
Given the previously established role of lAP in etv133 in- 
tegrin signaling (4, 7, 36, 54, 66, 75), we have investigated 
the potential role of the CBD-IAP interaction in modulat- 
ing the  133 integrin-mediated  adhesion and  spreading  of 
cells on vitronectin-(VN) coated surfaces. We have chosen 
a cell type that expresses IAP and the VN receptors etvl33 
and av135. Under appropriate conditions of low VN surface 
density,  the  initial  adhesion  event is  mediated  by ~v135 
while  subsequent  spreading  of  the  cells  requires  etv133. 
Spreading of unstimulated cells occurs only slowly, but 
addition of TS1, its recombinant CBD or the RFYVVM 
containing CBD peptides all greatly accelerate spreading 
with the concomitant tyrosine phosphorylation of focal 
adhesion kinase (FAK) and associated proteins. This lAP- 
dependent response to the CBD requires a pertussis toxin- 
sensitive, heterotrimeric G  protein. In contrast, constitu- 
tive spreading on high density VN surfaces is unaffected 
by pertussis toxin while both TSl-stimulated and constitu- 
tive spreading  are  blocked by inhibitors of PI-3 kinase, 
PKC, and tyrosine kinases. Thus, ligation of lAP by the 
TS1 CBD stimulates a Gi-like protein, which then appears 
to lead to the activation of PI-3 kinase, protein kinase C, 
and tyrosine kinases, elements common to the activation 
of integrin-dependent cell spreading in many systems (2, 
25, 34, 44, 55, 67, 69). 
Materials and Methods 
Reagents and Antibodies 
Human vitronectin, fibronectin, and collagens I  and IV were  obtained 
from Collaborative Biomedical Products (Bedford, MA). Fibrinogen was 
from Sigma Chem. Co. (St. Louis, MO). The rCBD was expressed as a 
Hisr-tagged protein in E. coli using the pQE30 vector (Qiagen, Chatsworth, 
CA) and purified by Ni-NTA chromatography (Dimitry, J., A. Jurkovich 
and  W.  Frazier,  manuscript  in  preparation).  Monoclonal  antibodies 
LM609 (anfi-av133) and PIF6 (anti-C~v135) were the generous gifts of Dr. 
D.  Cheresh (Scripps Research Institute). B6H12 and 2D3, anti-human 
IAP mAbs, have been previously described (7, 35, 36). mAbs 4G10 (anti- 
phosphotyrosine) and 2D7 (anti-p125  FAK, for immunoprecipitation) were 
from Upstate Biotechnology Inc.  (Lake  Placid,  NY).  Western blotting 
mAb against FAK, phosphotyrosine (PY20), and paxillin were the prod- 
ucts of Transduction Laboratories (Lexington, KY). All protein kinase in- 
hibitors were purchased from CalBiochem (La Jolla, CA). Rainbow pro- 
tein molecular weight markers and ECL Western blotting detection kit 
were from Amersham Corp. (Arlington Heights, IL). Anti-mouse IgG- 
agarose and other reagents were from Sigma. All peptides used were syn- 
thesized by the Protein and Nucleic Acid Chemistry Laboratory of Wash- 
ington University School of Medicine as described previously (17, 28). 
Peptides were evaluated by mass spectrometry before and after purifica- 
tion on high performance liquid chromatography. Human platelet TS1 
was purified as described (50). The amino acid sequences of the TS1 peptides 
used in this study are 4NK, KRFYVVMWKQVTQSKKY (native sequence 
1016-1029); 4N1K, KRFYVVMWKK; 4N7G, KRFYVVMGKK; 4NGG, 
KRFYGGMWKK; Hep III, TRDLASIARLRIAKGVNDNF (170-190); 
MAL III, SPWDIASVTAGGGVQKRSR (481-499). The synthetic pep- 
tides GRGDSP and GRGESP were from GIBCO-BRL (Gaithersburg, MD). 
Cell Culture, Adhesion, and Spreading 
C32 human melanoma cells (ATCC CRL 1585)  we're cultured in Gibco's 
Minimum Essential Medium (MEM) supplemented with 10% FCS. Mu- 
rine 3T3 fibroblasts (ATCC CRL 1658) were grown in DMEM plus 10% 
calf serum. Cell adhesion assays were performed as described previously 
(28). Briefly, 96-well plates were coated with substrates overnight at 4°C. 
C32 cells were harvested with 0.04%  EDTA in PBS  and washed twice 
with PBS. Cells were resuspended in Hepes-buffered saline (HBS; 20 mM 
Hepes/NaOH, pH 7.4, 0.15 M  NaC1,  1 mM CaC12, and 1 mM MgC12) al- 
lowed to adhere to the immobilized substrates for 90 min at 37°C in the 
presence of indicated additions in solution. After washing, the adherent 
cells were lysed in 1% Triton X-100 and quantified by endogenous phos- 
phatase activity with p-nitrophenyl phosphate as a substrate (46). For cell 
spreading experiments, glass chamber slides (LAbTek) or 12-well  tissue 
culture plates were coated with VN overnight at 4°C. C32 cells were har- 
vested for cell adhesion experiments and resuspended in HBS containing 
calcium and magnesium, both at 1 mM. Indicated additions of stimulators 
and  inhibitors  were  also  added  to  cell  suspensions at  this  time.  Cell 
spreading at 37°C was followed by washing, fixing, and staining with a 
LeukoStat stain kit (Fisher Scientific, Pittsburgh, PA). For the inhibition 
of cell attachment or spreading, C32 cells were pre-incubated with anti- 
bodies or inhibitors for 15 rain at 0°C before the assay. The required light 
activation of calphostin C (8, 19, 26) was also performed during this pre- 
incubation time. 
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Surface Receptors 
The expression of integrins and IAP was detected by fluorescent flow cy- 
tometry. C32 cells were harvested and washed as described above and re- 
suspended in C32 cell culture medium (with 10% FCS). The mAbs LM609 
vs ctvp  3, P1F6 vs ctv135,  or 2D3 vs IAP were added to aliquots of cell suspen- 
sions and incubated for 60 min at 4°C with rocking. After several washes 
in PBS, the aliquots were stained with FITC-labeled anti--mouse second- 
ary antibody (Pierce, Rockford, IL) for another 60 min in the cell culture 
medium, washed again with PBS, and then analyzed by flow cytometry. 
The second antibody and the mouse IgG, instead of primary antibody, 
were both used as negative controls and mAb W6/32 against HLA was the 
positive control. 
lmmunoprecipitation Studies 
C32 cell spreading was carried out as described above. At indicated times, 
cells were lysed by addition of 6x precooled modified RIPA lysis buffer. 1× 
RIPA lysis buffer is 50 mM Tris/HCl, pH 7.4, 0.15 M NaC1,  1% (wt/vol) 
NP-40, 0.5 % (wt/vol) sodium deoxycholate, 1 mM EGTA, ] mM Na3VO4, 
and protease inhibitors consisting of 10 I~g/ml each of antipain, pepstatin 
A, chymostatin, leupeptin, soybean trypsin inhibitor, aprotinin, and 1 mM 
phenylmethylsulfonylfluoride.  Cell lysis was completed by 30 min rocking 
at 4°C followed by microcentrifugation at top speed (13,000 rpm) for 30 
min. The soluble material from equal numbers of cells (or equal amounts 
of protein) was incubated with the specified monoclonal antibody for 3 h 
at 4°C and immunoprecipitated with anti-mouse IgG-agarose. The precip- 
itates  were  extensively washed  with  lx  RIPA  buffer,  dissolved,  and 
boiled in a small volume of SDS-sample buffer. 
Identification of  Immunoprecipitated Proteins by 
Western Blot Analysis 
Proteins were  separated by SDS-PAGE on 4-12%  or 8%  precast Tris- 
Glycine gels (NOVEX, San Diego, CA) and transferred to nitrocellulose 
membranes. Blots were blocked with 3% BSA plus 3% dried milk in TBS-T 
(0.1% Tween 20, 50 mM Tris/HC1, pH 7.4, 0.15 M  NaCl) overnight and 
probed with the indicated mAb at 1 tLg/ml in TBS-T plus 10%  blocking 
buffer for 1-2 h, washed, and incubated with a 1:10,000  dilution of horse- 
radish peroxidase-conjugated goat anti-mouse IgG  (Pierce).  Detection 
was by chemiluminescence. For  identification of coimmunoprecipitated 
protein(s), the same blot was stripped at 68°C (2x, 20 rain) in stripping 
buffer (62.5 mM Tris/HCl, pH 6.8,  2% SDS, 100 mM p-ME). The mem- 
brane was reprobed with the indicated mAb and processed as described 
above. 
Results 
Spreading of C32 Cells on VN 
The  spreading  of  C32  cells  was  examined  on  surfaces 
coated with a concentration range of VN (0.1-10  ixg/ml). 
Below ca. 3 i~g/ml VN, spreading was very slow, requiring 
1.5-2 h at 37°C to develop fully. At 5-10 ~g/ml spreading was 
relatively rapid, being complete within 30 min (not shown). 
The effect of soluble TS1, its recombinant CBD and pep- 
tides on C32 cell spreading on VN was tested. As seen in 
Fig. 1, all three agents dramatically accelerated spreading 
on suboptimal I  Ixg/ml VN-coated surfaces. Fig. 1 A shows 
the complete lack of spreading observed on VN (1 ixg/ml) 
at 30 min, while Fig. 1, B-D show fully spread, polygonal 
cells at 30 min in the presence of TS1, the rCBD and 4NIK 
in solution. This cell spreading data is quantified in Fig. 2. 
When  coated on the  surface in  the  absence of VN, TS1 
supports only very weak spreading of these cells, while the 
rCBD  and  4NIK (and  related  peptides  from the  CBD) 
support no spreading at all when immobilized (not shown). 
A  VN-coated  surface  is  required  for  spreading  to  take 
place since no spreading occurs on BSA-coated surfaces 
with  or  without  TS1,  the  rCBD,  and  its  peptides  (not 
shown). To determine if TS1 and its fragments could stim- 
ulate cell spreading on other matrix proteins besides VN, 
C32 melanoma cells were plated on concentration gradi- 
ents of fibronectin, collagens I and IV, gelatin, fibrinogen, 
and human and mouse laminin (LM) (as well as VN as a 
positive  control).  Concentrations  used  for  coating  were 
determined  in  preliminary  experiments  and  covered  a 
range from no visible spreading to fully spread cells during 
a  ]-h incubation. The C32 cells spread well on the higher 
densities of all these proteins except fibrinogen. The addi- 
tion of 50 IxM 4N1K or 50 ixg/ml TS1 did not stimulate cell 
spreading  at  any  density  of fibronectin,  collagens,  or  fi- 
brinogen.  However,  4N1K  and  TS1  did  stimulate  cell 
spreading on lower densities of gelatin and LM (and VN). 
Attachment to gelatin, like VN, was inhibited by blockade 
Figure 1.  TS1, rCBD, and 4NIK all accelerate C32 cell spreading on immobilized vitronectin.  C32 cells were allowed to spread on I ~g/ 
ml VN-precoated glass slides for 30 min at 37°C, followed by fixing and staining. The following were included in solution: (A), no addi- 
tion; (B), TS1 at 50 txg/ml; (C), recombinant CBD at 50 ~g/ml; (D), 50 I~M 4N1K peptide. BSA or peptides from other domains of TS1 did 
not affect cell spreading (not shown). 
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Figure 2.  The effect of TS1, rCBD, and peptides on C32 cell 
spreading.  C32 cell spreading assays were performed as in Fig. 1. 
After washing, fixing, and staining, cells with a diameter at least 
three times larger than that of round unspread cells were counted 
as spread cells. Results are expressed as the mean percentage 
(_+ SD) of spread cells compared to total attached cells in six high 
power fields from three separate experiments.  The peptide se- 
quences are described in Materials  and Methods and all peptides 
were used at 50 IxM in solution.  Peptides 4NGG (KRFYGGM- 
WKK) and 4N7G (KRFYVVMGKK) are "mutants" of 4N1K 
while  Mal  III and Hep III are cell-binding  peptides from two 
other domains of TS1. 
of ~vl35 and spreading was inhibited by anti-etvl33 (LM609) 
and  anti-IAP  (B6H12)  (not  shown).  Attachment  to  LM 
was blocked by an anti-131 mAb, not by LM609 or P1F6, 
and stimulated spreading on LM was blocked by B6H12 
but not by LM609 (not shown) suggesting that ligation of 
LM609 is not required for the action of IAP. To determine 
if TS1 and its CBD fragments could stimulate spreading of 
other cell types, murine NIH3T3 cells were tested for at- 
tachment and spreading on VN and the other matrix pro- 
teins above. As with the human C32 cells, TS1 and 4N1K 
stimulated spreading on low densities of VN, gelatin, and 
LM, but not other matrix proteins (not shown). 
The  possibility  that  contaminants  in  the  platelet  TS1 
preparation  were responsible for the  stimulation  of cell 
spreading is ruled out by the potent stimulatory activity of 
the rCBD produced in bacteria and purified on Ni-NTA 
resin (as opposed to heparin-agarose for TS1) and the ac- 
tivity of the synthetic peptide 4NIK. Other versions of the 
CBD  peptide containing  the  RFYVVM sequence  in  the 
context of more TS1 native sequence (17, 28) were all ac- 
tive  in  stimulating  cell  spreading,  while  peptides  from 
other  domains  of TS1,  including  other cell-binding pep- 
tides such as Mal III and Hep III, were without effect (Fig. 2, 
see Materials  and  Methods  for peptide  sequences).  The 
other VVM  containing  peptide  from the  CBD, FIRVV- 
MYEGKK  (17,  28),  was  also  active  in  stimulating  cell 
spreading. 
Our previous studies of cell attachment to the CBD pep- 
tides  indicated  that the  VVM sequence  is important for 
recognition of IAP (17, 18, 28). Thus "mutant" 4N1K pep- 
tides were synthesized in which residues between the KR 
and KK termini of 4NIK were replaced with G, and one in 
which the VV sequence was replaced with GG (4NGG). 
These peptides were tested in a  C32  cell adhesion  assay 
which reflects IAP-dependent binding of cells to the im- 
mobilized peptide  (18),  and  in  the  cell  spreading  assay 
(Fig.  2).  Peptides  4N3G  (KRFGVVMWKK)  and  4N7G 
(KRFYVVMGKK)  had  partial  activity  in  both  assays 
while peptide 4NGG (KRFYGGMWKK) was completely 
inactive in cell spreading (Fig. 2) and in binding cells (not 
shown). These results are important since the mutant pep- 
tides retain the precise charge distribution  of the parent 
peptide. 
In  summary,  these  data  are  important  in  several  re- 
spects: they demonstrate that the accelerated spreading is 
not due to adsorption of the TS1, the rCBD, or peptides to 
the surface in a nonspecific manner, since the rCBD and 
peptides support no spreading at all when directly coated 
on the surface, and only spreading on VN, LM, and gelatin 
exhibits the effect (and all surfaces are blocked with BSA). 
Second, only spreading on certain proteins, and thus medi- 
ated via certain integrins, is affected by the ligation of IAP 
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Figure 3.  Expression of lAP and integrins Ot.v~  3 and av135 on C32 cells. C32 ceils were stained with mAbs 2D3 (anti-lAP, left), LM609 
(anti-integrin tXv133, middle), and PIF6 (anti-integrin tXv~35, right) followed by fluorescein-conjugated goat anti-mouse IgG. The controls 
were stained with mouse IgG as the primary antibody, the distribution of which is plotted with each indicated mAb for comparison. 
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wells were coated with VN at the indicated concentrations overnight at 
4°C. C32 ceils were preincubated for 15 min with the indicated mAb or 
peptide, and then transferred to VN-coated wells for the cell attachment 
assay as in Materials and Methods. The mAbs were each present at 50 
~g/ml and the peptides GRGDSP or GRGESP were at 50 IxM. TS1 (50 
ixg/ml) or 4N1K peptide (50 I~M) were added right before plating 5 × 
104 C32 cells  per well.  After washing,  attached  cells  were quantified 
with endogenous phosphatase activity.  (A) Effect of TS1, mAbs, and 
peptides on C32 cell attachment to VN coated at 1 p.g/ml. (B) At higher 
surface densities of VN both mAbs LM609 and P1F6 are required  to 
block cell  adhesion. (C) 4N1K peptide does not augment av133-depen- 
dent cell adhesion when ~v135 is blocked with mAb PIF6. 
with the TS1 rCBD or peptides. Third, the effect is seen in 
another  species  of cell which is not transformed.  Fourth, 
the  VV sequence  of 4N1K is critical  for both binding to 
IAP and stimulation of cell spreading. 
Adhesion of (?32 Cells 
We  next  examined  the  receptors  used  by the  melanoma 
cells for interaction  with surfaces  coated with VN over a 
range  of concentrations  (0.1-10  ~g/ml).  Flow  cytometry 
was used to determine the levels of IAP and two common 
VN receptors etv133 and ctv135, expressed  on the surface of 
C32 cells. As seen in Fig. 3, IAP, O~v[33, and t~vl35 are all rel- 
atively abundant. Antibodies to these receptors were used 
to determine  which participated  in  cell  adhesion  to VN- 
coated  surfaces.  Fig.  4  A  shows  that  an  mAb  vs  Ctv135 
(P1F6) effectively blocked adhesion to VN coated at a low 
density (1 Ixg/ml) while anti-ctv133 mAb (LM609) had no ef- 
fect.  As  expected,  RGD  (but  not  RGE)  peptide  also 
blocked adhesion to VN. Thus, Ctvl33 is expressed  on C32 
cells (Fig. 3), but did not mediate binding at the low con- 
centration of VN used. We then examined the attachment 
of cells to higher surface densities of VN, and found that as 
the amount of VN adsorbed on the surface is increased, a 
larger fraction of adhesion is mediated  by av133 as judged 
by the fact that inhibition requires mAbs against both Otvl33 
and etvl35 (Fig. 4 B). 
To determine  if TS1 or 4N1K could increase the appar- 
ent  affinity or avidity of etv133, adhesion  to VN  was per- 
formed in the presence of TS1 and the peptide.  Addition 
of TS1 or 4N1K peptide to the soluble phase had no effect 
on the  number  of cells  adhering  to VN  (Fig.  4 A), even 
though TS1 and an active CBD cell-binding peptide 4N1K, 
bound cells quite well when they were coated directly on 
the  plastic,  while  several  control TS1  peptides  and  BSA 
did  not bind  cells  to  an  appreciable  extent  (not  shown). 
Two anti-lAP mAbs (B6H12 and 2D3) also had no effect 
on cell attachment  to VN (Fig.  4 A), consistent with  the 
lack of effect of peptide 4N1K, an lAP ligand, on the num- 
ber of cells adhering. If etv133 were activated by 4N1K, the 
proportion of adhesion mediated by av133 would be greater 
in the presence of the peptide. However, the degree of in- 
hibition  by LM609 was not increased  at  any VN surface 
density tested  (not shown). Also, when av135 was blocked 
by P1F6 mAb, the addition of 4N1K did not increase cell 
adhesion to VN, indicating a lack of effect on adhesion via 
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tors (see Materials and Methods for details), cell spreading was allowed to proceed for 30 min on 1 t~g/ml  VN-coated glass slides. (A) 50 
p,M soluble 4N1K stimulated  C32 cell spreading as before; (B) mAb LM609 at 20 ~g/ml completely abolished spreading stimulated  by 
4N1K. mAb 2D3, a nonfunction-blocking  mAb against IAP, had little effect at 100 txg/ml (C) while B6H12 (D), an anti-lAP function- 
blocking mAb, completely prevented spreading at 100 ixg/ml. The PKC inhibitor  calphostin  c (at 100 nM) (E) and wortmannin (at 10 
nM) (F), a PI-3 kinase inhibitor, both abolished spreading stimulated by 4N1K as well as the spreading which occurred on higher density 
VN without 4N1K (not shown). 
Otv[~  3 or  any other receptor (Fig. 4 C). Thus, it appears that 
TS1 and 4NIK peptide do not increase the affinity/avidity 
of av[~3 even though TS1  and its CBD derived fragments 
have dramatic effects on cell spreading on VN (Fig. 1). This 
suggests that effects on cell spreading are mediated by stim- 
ulation of an IAP-dependent signaling pathway by TS1. 
Characterization of TS  I-stimulated Spreading 
We first determined the effect of mAbs on the 4NIK stim- 
ulated spreading of C32 cells. Fig. 5 A  shows the stimula- 
tion (at 30 min) by 50 IxM 4NIK of cells attached to 1 p.g/ml 
VN.  Figs.  5  B  and  6  show  that  mAb  LM609  directed 
against the VN receptor Otv[33, results in complete inhibi- 
tion of cell spreading, even though, as seen in Fig. 4 A, ini- 
tial  attachment of the  cells to VN is mediated solely by 
etv[35. Thus, it appears that the stimulation of spreading is 
mediated by etv133. At higher coating concentrations of VN, 
where spreading is more rapid and stimulation by TS1  is 
not  as easy to discern, spreading is also blocked by anti- 
body to Otv~  3 and anti-O~vl35 has no effect (not shown). This 
suggests that higher surface densities of VN alleviate the 
need for an  activating stimulus,  perhaps by cross-linking 
the integrin (55). To determine if av135 might become acti- 
vated and contribute to cell spreading, cells were allowed 
to attach to VN for 15 min in the absence of an mAb or pep- 
tide, which they cannot do in the presence of mAb P1F6 
(Fig. 4 B). Then, either mAb LM609 or PIF6 was added 
along with a  stimulatory peptide (4N1K).  After an addi- 
tional 30  min, cells in  control mAb or P1F6  had  spread 
equally  well  while  mAb  LM609  completely  blocked 
spreading  as  before  (Fig.  6).  That  the  stimulation  of 
spreading by TS1 requires IAP is seen in Fig. 5, C and D. 
The function-blocking anti-lAP mAb B6H12 inhibits the 
stimulated spreading while the nonfunction blocking anti- 
lAP mAb 2D3 has no effect. These results are quantified 
in  Fig.  6.  TS1,  the  rCBD  and  4N1K  all  stimulate  cell 
spreading on VN to the same extent: ~80%  of total cells 
spread in 30 min vs ca. 15% spread with no stimulation. As 
seen in Fig.  6,  both mAbs LM609  and B6H12 block the 
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Figure 6.  Quantitative analysis of C32 cell spreading on immobi- 
lized vitronectin.  C32 cell spreading assays were performed as in 
Fig. 5 and quantified  as Fig. 2. "*" indicates spreading in the ab- 
sence of 4NIK (negative control).  50  p.M 4NIK peptide  was 
present in all other cases plus: mouse IgG, 100 Ixg/ml; LM609, 
20 Ixg/ml;  B6H12, 100 ~g/ml; 2D3, 100 ixg/ml. In separate experi- 
ments, C32 cells were allowed to attach to VN for 15 min in the 
absence of a mAb or 4N1K peptide. Then, either mAb LM609 or 
P1F6 was added along with peptide 4N1K followed by an addi- 
tional 30 min spreading incubation.  Data from these experiments 
are indicated with "**" 
stimulation of spreading to about the same extent, nearly 
the  unstimulated  level. The  same  results  were  obtained 
when spreading was stimulated by TS1  at 50  ~g/ml (not 
shown).  These  data  clearly  indicate  that  both av~3  and 
IAP are required for the stimulation of cell spreading on 
VN by the CBD of TS1. One possibility is that IAP liga- 
tion causes an increase in the affinity or avidity (by cluster- 
ing) of Otvl~3. If this occurs, then 4N1K and TS1 should en- 
hance the adhesion of cells to low density immobilized VN. 
As seen in Fig. 4, A and C, this does not occur. Over a wide 
concentration  range of VN coating, 4N1K peptide never 
increases adhesion,  only spreading. These results further 
suggest that etvl~  3 can form a  signal transducing  complex 
with IAP, as observed in other systems (4, 7,  36,  54,  66, 
75), which can lead to the stimulation of cell spreading. 
Effect of TS1 and 4N1K on Tyrosine Phosphorylation 
Integrin-mediated spreading of many cell types is accom- 
panied by the phosphorylation on tyrosine residues  of a 
set of cellular proteins involved in focal adhesion assembly 
and turnover (9, 21, 23, 25, 39, 52). These include focal ad- 
hesion kinase (pp125, FAK) and paxillin (pp60-70 triplet). 
We thus wanted to determine if the stimulated cell spread- 
ing observed with TS1 and its CBD led to tyrosine phos- 
phorylation  of any  such  proteins.  To  do  this,  C32  cells 
were allowed to spread on VN-coated surfaces (1  ~g/ml) 
in the absence (HBS) or presence of TS1 or 4N1K for var- 
ious times when the cells were rapidly lysed, immunopre- 
cipitated  with  an  anti-phosphotyrosine  (PY)  mAb,  the 
precipitated  proteins  run  on  SDS-PAGE  and  Western 
blotted with the anti-PY mAb 4G10. As seen in Fig. 7 A, 
TS1  and 4N1K stimulate the tyrosine phosphorylation of 
several proteins with Mr of ca. 125 kD (a), ca. 90 kD (b), 
and a cluster at 60-70 kD (c) running just above the mAb 
heavy chain.  In an attempt to identify these  phosphory- 
lated proteins, specific antibodies  to known signal trans- 
duction  components were employed. Fig.  7 B  shows  the 
results of an experiment in which cell lysates were treated 
like those in Fig. 7 A except that the precipitating antibody 
was anti-FAK mAb 2D7  (51).  Here it is seen that phos- 
phorylated FAK detected with mAb 4G10, appears much 
earlier in the time course and accumulates to a greater ex- 
tent  in  cells  spreading  on  VN  in  the  presence  of either 
4NIK or TS1. In addition, other phosphoproteins are seen 
presumably as a result of their association with FAK, with 
Mr of ca. 140, 95, and 90 kD. This latter 90-kD protein is of 
interest  because it becomes phosphorylated  earlier  than 
FAK itself, and in the TS1- and 4N1K-treated cells it ei- 
ther dissociates from FAK or becomes dephosphorylated 
(or both) by the last time point. When C32 cells are main- 
tained  in suspension  so that focal adhesion  formation is 
prevented, the addition of 4N1K causes rapid and intense 
tyrosine phosphorylation of this 90-kD protein, but phos- 
phorylation of FAK and  other proteins is not  observed. 
This also suggests that phosphorylation of this 90-kD pro- 
tein is an early event following IAP ligation. Preliminary 
experiments indicate  that  this  pp90  species  is not  phos- 
phatidylinositol-3 kinase. 
Pertussis Toxin Specifically Inhibits Cell Spreading 
Stimulated by 4N1K and TS1 
To begin defining a mechanism for the stimulation of av133- 
dependent  cell spreading by ligation of IAP, we tested a 
number of well characterized inhibitors of signal transduc- 
tion enzymes. Even though  IAP can associate with av133, 
previous studies have indicated that signal transduction in- 
volving PKC is required for modulation of integrin-medi- 
ated  functions  (75).  As  noted  above,  PKC  activation  is 
also a common element in integrin-mediated cell spread- 
ing (31, 69). We thus tested a number of protein kinase in- 
hibitors for their effect on the rapid spreading elicited by 
4N1K and TS1. These included six ser/thr kinase inhibitors 
of varying specificities (HA1004, chelerythrine, H7, K252b, 
Ro-31-8220, and calphostin C, see Materials and Methods 
for details). Of these, the specific protein kinase C inhibi- 
tor calphostin C  completely inhibited  the stimulated cell 
spreading (Fig. 8) at a  concentration of 100  nM which is 
only twice  the  reported  ICs0 (26).  Chelerythrine,  also  a 
PKC inhibitor, was effective at higher concentrations (Fig. 8). 
Moreover, PMA treatment of C32 cells adherent to sparse 
VN coatings rapidly induced cell spreading, demonstrating 
that direct PKC activation could induce the same behavior 
as TS1. However, the PKC inhibitors (above) also blocked 
the rapid constitutive spreading on high densities of VN in 
the absence of TS1 or its peptides. This along with previ- 
ous reports from others (31, 69) indicates that PKC plays a 
general role in spreading, and is not specific to the action 
of lAP.  Wortmannin,  genestein,  and  herbimycin A  also 
abolished  cell  spreading  at  appropriate  concentrations 
(Fig. 8). However, as with PKC inhibitors (above), none of 
these inhibitors were specific for TSl-induced cell spreading. 
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ulate protein tyrosine phosphorylation. 
C32 cells were allowed to spread on 1 
i~g/ml VN-coated 12-weU tissue culture 
plates with or without 50 txg/ml TS1 or 
50  ~M 4N1K peptide in  solution.  At 
the  indicated  times  (min)  cells  were 
lysed  in  RIPA buffer  (see  Materials 
and  Methods).  Soluble  material from 
equal numbers of cells (equal amounts 
of  protein)  was  incubated  with  anti- 
phosphotyrosine  mAb  PY20  (A)  or 
anti-p125 FA~ mAb 2D7 (B) and precip- 
itated  with  anti-mouse  IgG  agarose. 
SDS-PAGE on 4-12% (A) or 8% (B) 
acrylamide gels was followed by West- 
ern blotting with anti-phosphotyrosine 
mAb 4G10 with ECL detection. 
The possible involvement of the Gi/Go class of hetero- 
trimeric G  proteins in the stimulation of cell spreading on 
VN was tested by incubating the C32 cells overnight in B. 
pertussis toxin (20-300 ng/ml). The cells were then plated 
on 1 p~g/ml VN-coated slides in the presence or absence of 
TS1 and 4N1K peptide as above. Interestingly, the pertus- 
sis toxin pretreatment (all concentrations)  strongly inhib- 
ited the ability of TS1 and 4N1K to stimulate cell spread- 
ing  (Fig.  9,  A-D,  and  G).  Unlike  inhibition  of tyrosine 
kinases, PKC and PI-3 kinase, the blockade of Gi-like pro- 
teins with pertussis toxin did not affect unstimulated, rapid 
spreading on high density VN suggesting that the G  pro- 
tein(s) act more proximally to IAP and upstream of PKC, 
tyrosine  kinases,  and/or  PI-3  kinase.  The  carbohydrate 
binding B oligomer portion of pertussis toxin has been re- 
ported to be responsible for some effects of the toxin (24). 
We thus tested the isolated B oligomer (30-300 ng/ml) and 
found that at all concentrations tested, the B  oligomer of 
pertussis toxin was without effect on cell spreading (Fig. 9 G). 
To ensure that the failure of the whole toxin-treated cells 
to spread in response to TS1 and 4N1K was due to the spe- 
cific blockade  of a  heterotrimeric  Gi  protein  and  not  a 
general cytotoxic effect, toxin-treated ceils were plated on 
VN and stimulated with PMA.  Spreading of the cells en- 
sued immediately and proceeded to the same extent noted 
when C32  cells were treated with PMA alone  (Fig.  9, E 
and  G). In contrast, cells treated with wortmannin could 
not be stimulated to spread with short-term PMA treat- 
ment (Fig. 9, F and G). Thus, IAP appears to use a Gi pro- 
tein pathway to access the common pathway described by 
others  in  which  activation of PKC, PI-3 kinase,  and  ty- 
rosine kinases leads to cell spreading mediated by a num- 
ber of integrins in several cell types (3, 13, 20, 56). 
Discussion 
The data presented here provide insight on a novel mecha- 
nism by which  TS1  can  affect integrin-mediated  cellular 
processes involved in  normal development, homeostasis, 
and pathogenesis. It is thus appropriate to view TS1  and 
other  TS  family members which  contain  the  sequences 
that bind lAP as acute modulators of integrin function. In 
fact,  this  modus  operandi  fits  well  with  accumulating 
knowledge  about  the  expression  and  biological  roles  of 
TS1. For example, TS1  has  an acute function  in platelet 
aggregation (see below), and it influences the motility of a 
number of migratory cell types, particularly during the in- 
flammatory response (37, 38, 63, 64, 71, 72). Its expression 
in endothelial cells is tightly regulated where it can inhibit 
angiogenesis if expressed early in the process, but may be 
important in endothelial cell differentiation into capillar- 
ies (58, 65). TS1  expression is acutely regulated by cyto- 
kines and growth factors in several cell types (6, 10, 32) as 
exemplified in vivo during wound healing (47, 48) and in 
development (22). This acute regulation of TS1 synthesis 
and secretion is characteristic of agents which regulate un- 
derlying processes of adhesion and motility. 
In this report we first establish that the effect of TS1/IAP 
ligation is on the spreading of cells and not on their adhe- 
sion. Interestingly, the interaction of the C32 cells with VN 
is a two step process at low densities of VN, with etv[35 sup- 
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Figure  8.  Effect of inhibitors  on cell spreading  stimulated  by 
4N1K. Peptide 4N1K was present in all cases (except the DMSO 
negative control marked with "*"). (Left to right) DMSO, (con- 
trol vehicle); wortmannin  10 nM; calphostin  C,  100 nM; chel- 
erythrine 7 I~M (L) and 21 IxM (H); genistein 25 txM (L) and 75 txM 
(H); herbimycin 9 I~M (L) and 27 txM (H); HA1004 390 p.M. See 
Materials and Methods for protocols. 
plying the initial binding interaction and av133 leading to 
spreading. At high densities of VN, both integrins partici- 
pate in cell adhesion as indicated by mAb inhibition pro- 
files (Fig. 4). We could find no evidence that %135 partici- 
pates in spreading in these cells. In FB carcinoma cells, 
%[35 can be stimulated by PMA treatment to support cell 
spreading on VN (25), but this effect requires transcrip- 
tional activation via NF-KB and synthesis of new proteins, 
a process that takes several hours (73). The enhancement 
of spreading by TS1 reagents occurs very rapidly, within 
minutes, and is specific for the native RFYVVM sequence 
as shown with control and mutant peptides. The activity of 
the  recombinant  CBD  and  whole  TS1  further indicates 
that this effect is a property of the native TS1 molecule. 
The stimulation of spreading via lAP is seen with murine 
3T3 cells as well as the transformed human melanoma line 
C32  employed in  most  of our experiments. Hence,  this 
phenomenon is not unique to a single species of cell or to 
transformed cells. Spreading on other matrix proteins such 
as collagens, fibrinogen, and fibronectin mediated by inte- 
grins other than C~vl33 is not augmented by TS1 or 4N1K in 
either C32 or 3T3 ceils. Interestingly, cell spreading on LM 
is stimulated by the TS reagents, an effect currently under 
investigation. 
The properties of the TSl-enhanced spreading on VN 
are consistent with previous information about IAP func- 
tion obtained with the function-blocking mAb B6H12 in 
leukocyte systems where lAP was seen to be required for 
signal transduction resulting in effects on the function of 
~5131 integrin in phagocytosis (4). In both endothelial cells 
(54) and fibroblasts (66), IAP inhibition blocks a calcium 
transient which may augment PKC activation. B6H12 treat- 
ment of either the PMNs or the HUVECs blocks the trans- 
migration of PMNs  across HUVEC monolayers in vitro 
(11). We have shown that the 4N1K peptide and TS1 stim- 
ulate  HUVEC  chemotaxis  on  gelatin-coated  filters,  an 
etv133-dependent process, and this chemotaxis is blocked by 
B6H12 (18).  Others have noted the similarities between 
integrin-dependent cell migration and cell spreading (15, 
55), and our results with the HUVEC chemotaxis system 
indicate that the inhibitors which we have found to block 
the stimulation of C32 cell spreading also block lAP-depen- 
dent HUVEC chemotaxis (Tolsma, S., N. Bouck, M.B. Finn, 
and W. Frazier, manuscript in preparation). 
While  the  use  of inhibitors  cannot  provide definitive 
proof of the essential role of a  given signal transduction 
component in a pathway, we have used a panel of inhibi- 
tors here as a starting point to begin assessing the types of 
systems which TSI-IAP ligation might affect. In fact our 
results agree with recent data from other groups who have 
found that PKC activation may be a universal intermedi- 
ate step in cell spreading (2, 25,  34,  44,  67,  69) whether 
"constitutive" or "stimulated" as seen here. Accumulating 
data using wortmannin also implicate PI-3 kinase as an im- 
portant  component  of integrin-mediated  cell  activation 
(30, 59, 74). Our data indicate that TS1 and lAP represent 
a previously unknown way of modulating these constitu- 
tive signaling pathways that lead to cell spreading. More 
interesting from a  mechanistic standpoint  is  the  finding 
that  Gi-like proteins are required for the lAP-mediated 
stimulation,  and  that pertussis  toxin does not  block the 
constitutive spreading response  as  seen on high  density 
VN. Of all inhibitors used in signal transduction research, 
the cholera and pertussis toxins can claim specificity due 
to their recognition of their substrates via the enzymatic 
subunits of the toxins. We have shown here that pertussis 
toxin  specifically blocks  the  TS1/IAP-mediated  stimula- 
tion of spreading on VN. The carbohydrate binding B oli- 
gomer has no effect, and the blockade is bypassed by di- 
rect  PKC  stimulation  with  phorbol  ester  ruling  out  a 
general cytotoxic effect (Fig. 9). The constitutive spread- 
ing on high density VN is not affected by pertussis toxin, 
again ruling out a toxic effect, and, more importantly, indi- 
cating that the G protein activated step is proximal to lAP 
and upstream of PKC activation. Mansfield et al.  (1990) 
reported that the migration of leukocytes toward TS1  is 
sensitive to pertussis toxin and mAb C6.7 directed to the TS1 
CBD (37, 38). Our preliminary data indicate that chemo- 
taxis  of several cell types, including  monocytes, toward 
4N1K  is  pertussis toxin sensitive  (W.A.  Frazier,  unpub- 
lished data). This toxin is known to cause the ADP-ribosy- 
lation of the et subunit of Gi isoforms 1, 2, 3, and Go, as 
well as the Ga subunits of transducins 1 and 2 (43). It is 
unlikely (but not impossible) that the transducins  or Go 
are  expressed in  C32  cells,  thus  narrowing  the  field of 
likely candidates to the GOql.  3. We are currently investigat- 
ing the expression of Get subunits in C32 cells and whether 
there is a direct interaction between lAP and a G i protein. 
The signaling pathway proposed here for IAP costimu- 
lation of etv133-mediated cell spreading is remarkably simi- 
lar to the pathway reported by Shattil and coworkers (57) 
to  explain  the  costimulation  of t~iib133-mediated platelet 
spreading on fibrinogen-coated surfaces.  In  that system, 
unstimulated  platelets  adhere  to  fibrinogen  but  do  not 
spread in the presence of apyrase, an ADP scavenger, un- 
less a costimulatory signal is provided by epinephrine or 
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Figure  9.  Effects  of pertussis  toxin  and  phorbol  ester  on  C32  cell 
spreading on vitronectin. C32 cells were allowed to spread on I ixg/ml 
VN in the absence (A, C, and E) or presence (B, D, and F) of 50 ~M 
4N1K peptide. The phorbol ester PMA alone at 10 ng/ml (C) caused ex- 
tensive spreading of the cells. After overnight treatment with pertussis 
toxin (see Materials and Methods), 4N1K was no longer able to stimu- 
late cell spreading (D), however, a 10-min pretreatment with 10 ng/ml 
PMA could cause spreading of the pertussis toxin-treated cells  (E). 
PMA (10 min, 10 ng/ml) was not able to reverse the block to spreading 
imposed by wortmannin (10 nM) (F). (G) Quantification of effects of 
these inhibitors and controls. PT-B refers to the B oligomer of pertussis 
toxin present at the same concentration used for pertussis toxin in D 
above. 
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tors are coupled to heterotrimeric Gi proteins which lead 
to  the  activation  of  PKC  via  lipid  mediators  including 
arachidonate, thromboxane  A2 (which itself binds to an- 
other  heptahelical  receptor),  and  diacylglycerol.  In  this 
context it is noteworthy that the first reported function for 
the  CBD  of  TS1  was  that  of  stimulation  of  secondary 
phase  or  secretion  dependent  platelet  aggregation.  This 
was based on inhibition by the mAb C6,7 directed against 
the CBD (14). Several TS1 receptors have been identified 
on platelets and several explanations for the role of TS1 in 
platelet  aggregation  have  been  proposed  (68).  None  of 
these satisfactorily explain the inhibition by the anti-CBD 
mAb C6.7. lAP is present on platelets in abundance and 
associates  with  alibi33 (7).  Based  on  the  similarities  be- 
tween  the  lAP  signal  transduction pathway in  C32  cells 
presented here and the costimulatory pathway in platelets 
(57), we suggest that a role of TS1 in platelets is that of an 
integrin costimulator acting through IAP. Experiments to 
test this hypothesis are currently in progress. 
In conclusion, we have  identified  previously  unknown 
functions for both TS1 and IAP in costimulating c~vl33 inte- 
grin-mediated  cell  spreading.  The  involvement  of  PKC 
and PI-3 kinase in cell spreading (2, 25, 34, 44, 55, 67, 69) 
appears to be a general constitutive mechanism. TS1 bind- 
ing to lAP can modulate or augment this pathway by acti- 
vating a  Gi type heterotrimeric  G  protein.  This suggests 
that TS1  acting through IAP may have a general role in 
modulating  cell  motility  and  other  matrix  interactions 
where integrins are the primary mediators. This model for 
TS action provides a new perspective on the role of TS1 in 
many cases  where  it is transiently synthesized and/or se- 
creted  at  sites  of  tissue  development  or  remodeling, 
wound healing, inflammation, and angiogenesis. 
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